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Abstract
Background: There are high rates of sexually transmitted infections (STIs) in ethnically diverse, sexually active
students aged 16–24 years attending London further education (FE) colleges. However, uptake of chlamydia
screening remains low. The TnT study aims to assess the feasibility of conducting a future trial in FE colleges to
investigate if frequent, rapid, on-site testing and treatment (TnT) reduces chlamydia rates. This article presents the
statistical analysis plan for the main study publication as approved and signed off by the Trial Management Group
prior to the first data extraction for the final report.
Methods/design: TnT is a cluster-randomised feasibility trial conducted over 7 months with parallel qualitative and
economic assessments. Colleges will be randomly allocated into the intervention (TnT) or the control group (no TnT).
Six FE colleges in London will be included. At each college for 2 days, 80 consecutive sexually active students aged
16–24 years (total 480 students across all six colleges) will be recruited from public areas and asked to provide baseline
samples. One and 4 months after recruitment intervention colleges will be visited on two consecutive days by the TnT
team where participating students will be texted and invited to come for same-day, on-site, rapid chlamydia testing
and, if positive, treatment. Participants in the control colleges will receive ‘thank you’ texts 1 and 4 months after
recruitment. Seven months after recruitment, participants from both groups will be invited to complete questionnaires
and provide samples for TnT. All samples will be tested, and same-day treatment offered to participants with positive
results. Key feasibility outcomes include: recruitment rates, testing and treatment uptake rates (at 1 and 4 months) and
follow-up rates (at 7 months).
Trial registration: ISRCTN 58038795. Registered on 31 August 2016.
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Background
There are high rates of sexually transmitted infections
(STIs) in ethnically diverse, sexually active students aged
16–24 years attending London further education (FE)
colleges [1–4], with around 8% testing positive for Chla-
mydia trachomatis. However, uptake of chlamydia
screening remains low: below 30% annually in 16–
24-year-olds in England [4, 5]. Although chlamydia and
gonorrhoea primarily affect young people, the conse-
quences of infection such as infertility, chronic pelvic
pain or epididymitis can last a lifetime. It is estimated
that 10–16% of women with untreated chlamydia will
develop clinical pelvic inflammatory disease of whom 8%
will have an ectopic pregnancy and 11% will suffer from
tubal-factor infertility [6]. The cost of chlamydia and
gonorrhoea to the NHS is estimated to be over £100
million each year.
Barriers to reducing chlamydia rates include low up-
take of testing by those most at risk [5, 7] (such as teen-
agers, people from ethnic minorities and people who are
socioeconomically deprived), and long delays in receiv-
ing a positive diagnosis or attending for treatment [8, 9].
Introducing rapid, on-the-spot chlamydia tests and treat-
ment into the community could make it easier for young
people to get tested and treated faster before they can
pass on their infection. It might also prevent complica-
tions [10, 11]. These novel tests can have 99% sensitivity
and 99.4% specificity [12], and studies have demon-
strated their feasibility in remote communities [13].
However, there have been no UK trials of rapid sexually
transmitted infection (STI) tests and same-day, on-site
treatment in non-healthcare settings.
Objective
To assess the feasibility of conducting a future trial in
further education (FE) colleges to investigate if frequent,
rapid, on-site testing and treatment (TnT) reduces chla-
mydia rates in sexually active male and female students
aged 16–24 years.
Methods and design
TnT is a cluster-randomised feasibility trial conducted
over 7 months with parallel qualitative and economic as-
sessments. The outcome is measured within one aca-
demic year to optimise follow-up.
Both the current feasibility study and a future, de-
finitive trial will be cluster randomised. This is to
avoid contamination, which may arise if students were
individually randomised within the same college, as
sexual partners could potentially be allocated to dif-
ferent groups. The cluster design also reflects how
TnT would be rolled out in practice, with college
visits once each term.
Six FE colleges in London will be included. Colleges
were included based on their high proportion of black
and ethnic minority students and an even gender split,
as well as their close proximity to St George’s, University
of London (SGUL) [3]. At each college, for 2 days, 80
consecutive sexually active students aged 16–24 years
will be recruited from public areas (total 480 students
across all six colleges). Research assistants will approach
students in common room areas. The students will be
asked if they are willing to help with research on sexual
health. Potentially eligible students will be invited to
come to the study table where recruiters will explain
that as the study is about chlamydia and sexually trans-
mitted infections, only students who have had penetra-
tive sexual intercourse should consider taking part.
Those who are interested will be given a patient infor-
mation sheet and consent form to read and encouraged
to ask questions.
Exclusion criteria
 Students who self-report never having had penetra-
tive sexual intercourse
 Students with severe learning disability as identified
by college identification badges
Randomisation will take place once recruitment is
completed and baseline data collected for all colleges.
Colleges will be randomly allocated into the intervention
(TnT) or the control group (no TnT) in a 1:1 (i.e. equal
allocation) ratio by the trial statistician. The randomisa-
tion will be constrained to ensure that three colleges are
allocated to each group. Recruitment of colleges and
participants will take place prior to group allocation to
ensure allocation concealment and prevent selection
bias, and, therefore, the baseline data collection from
students will be blind to treatment group.
Participants will be asked to provide samples (urine
for males and self-taken vaginal swabs for females) at
baseline and after 7 months and to complete question-
naires on sexual lifestyle and healthcare use at both time
points. Questionnaire data will be collected at the col-
lege using encrypted tablet computers. As a contingency,
paper questionnaires will be used as back up. All partici-
pants will be informed that baseline samples will not be
tested for 7 months and will be advised to get screened
separately from the study in the event that they are allo-
cated to the control group.
One month after recruitment, each intervention cam-
pus will be visited on two consecutive days by the TnT
team. (These will be the same days of the week as at re-
cruitment to optimise participating student attendance.)
The 80 participating students in each campus will be
invited to provide a sample, but this time the sample will
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be tested immediately on site using the Cepheid Gen-
eXpert system which takes 90 min. Participants will
be given a card designed by the user group contain-
ing information about STIs, and links to the Brook
sexual health website: www.brook.org.uk. Negative re-
sults will be sent to participants by text. Participants
with positive chlamydia results will be telephoned and
invited to come to the college nurse’s room for treat-
ment, partner notification, advice and follow-up by a
visiting dispensing (under Patient Group Directive)
nurse health adviser. Participants with infections will
be asked to bring any sexual partners who attend the
college so they can also be tested and treated. The
nurse health adviser will arrange for participants who
are positive for gonorrhoea to be reviewed by a clin-
ician on the same or the next day at a genitourinary
medicine (GUM) clinic. This is for clinical examin-
ation, so that repeat samples can be taken to evaluate
gonorrhoea resistance to antibiotics, for intramuscular
injection of antibiotics and for partner notification.
All participants in the three intervention campuses
will be invited to provide repeat samples for on-site
TnT 4 months after recruitment (i.e. the next college
term), when all the procedures described above will
be repeated.
Participants from the three control colleges will not
get TnT but will receive texts 1 and 4 months after re-
cruitment thanking them for being in the study.
All participants will be asked to provide samples and
to complete questionnaires at college at 7 months. Test-
ing at 7 months is required in the proposed full trial to
calculate the main outcome (prevalence of chlamydia),
and is included here to test the feasibility of collecting
these data. Treatment will also be offered to those diag-
nosed with infection at 7 months. This is not part of the
assessed intervention, but is offered to enhance screen-
ing uptake, and participation in general among the con-
trol group. In addition, at the end of the study, stored
baseline samples will be tested using standard tests, and
participants with positive results will be contacted by the
health adviser. Those not attending for follow-up will be
sent an SMS text with a link to the final questionnaire
to be completed online. They will also be telephoned
and offered the opportunity to provide a sample for rou-
tine (not rapid) testing either in college at a prearranged
time or by post.
Outcomes
1. The outcomes of this study include key values to
inform feasibility, sample size and timescales of a
full trial of TnT in FE colleges. These include:
(a). Recruitment rates and associated outcomes:
 Of the total number of students assessed for
eligibility the proportion who are eligible are
asked to participate in the study
 Of those eligible the proportion recruited to
the study
 The time to recruit 80 students at each
college
 Age, gender and ethnicity of students
recruited versus students not recruited
(b).Testing and Treatment uptake rates (1 and 4
months after recruitment) (intervention colleges
only):
 Of the total number of students recruited in
the intervention group the proportion that
return at 1 month (and 4 months) and
provide a sample for testing
 Of those tested, the proportion with positive
test results and the proportion treated
 The time from test to informing the
participating student of the result
 The time from test to treatment of positives
 The number of partners confirmed treated
per index case
(c). Follow-up rates (at 7 months):
 Of the total number of students recruited the
proportion that return at month 7 and
provide a sample for testing
 Of those tested, the proportion with positive
test results and the proportion treated
 Of the total number of students recruited,
the proportion that complete the final
questionnaires (including data on healthcare
usage)
(d).Prevalence of chlamydia in participants at each
college at baseline and at 7 months
2. A perspective on the acceptability of TnT in FE
colleges emerging from qualitative interviews,
including barriers and facilitators to uptake and
possible harms. This will be described in more
detail elsewhere.
3. Estimate of the cost per person screened and
treated in TnT versus usual care. Detailed analysis
plans for these health economic assessments will be
documented separately by the trial’s health
economist.
Sample size calculation
Assuming a 30% recruitment rate [14], 1600 students
will be approached to recruit 480 overall (80 per college
across six colleges: three intervention colleges and three
control colleges). Estimates of testing uptake at 1 and
4 months (intervention colleges only) will be based on
240 students, and at 7 months will be based on 480
students (all colleges).
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Teare et al. recommend that 60 to 100 subjects are
sufficient to estimate an event rate with acceptable pre-
cision in a feasibility study [15]. Prevalence of chlamydia
at baseline will be estimated separately for each of the
six colleges (80 students per college), and these preva-
lence figures will be used to inform the intraclass correl-
ation coefficient (ICC), required for the sample size
calculation for the main study. From our previous re-
search involving 11 colleges, the ICC was estimated to
be 0.005 (95% confidence interval − 0.013 to 0.026) [3].
Adding data from another six colleges will improve the
precision of this ICC, reducing the width of the confi-
dence interval by around 20%.
Assuming 70% followed up at 7 months, final esti-
mates of chlamydia prevalence would be based on 168
students in each of the intervention and control groups
[3]. The study is not powered to find a statistically sig-
nificant difference in chlamydia rates between groups,
but may provide useful information on possible effect
size to inform future sample size calculations.
Statistical analyses
Trial profile
The flow of participants will be displayed in the Consoli-
dated Standards of Reporting Trials (CONSORT) flow-
chart as shown in Fig. 1 [16].
Data management and quality assurance
Contact details will be collected on paper consent forms
which will then be entered and stored on an encrypted
Access database by authorised research personnel. At-
tendance and laboratory data will be initially recorded
on paper worksheets and then entered, by designated re-
search personnel, to an online database (REDCap) [17]
hosted by SGUL. Questionnaire data will be entered
electronically using the REDCap mobile application on
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) trial flowchart
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encrypted tablets where tablets are available, or on paper
as a back-up. At the end of the visit to each college, the
data will be uploaded or entered to the SGUL servers by
designated research personnel.
Research coordinators and the trial manager will
periodically perform basic checks, such as examining for
improbable values and data completeness, as well as
random checks on the data. Anomalies will be explored
and checked with original source data.
After the last patient has been followed up, all queries
resolved and all data fields completed with data or
missing data codes, the database will be locked for final
analysis and this process will be overseen by the trial
statisticians.
General analysis principles
The analysis principles outlined will be followed as
closely as possible in the analysis and reporting of trial
data; the statistical analysis plan is not intended to re-
strict exploratory or other sensible and standard report-
ing practices. There are no plans for any formal
comparisons between treatment groups until final data-
base lock. Analysis will be undertaken by the trial
statistician.
Since this a feasibility study no statistical significance
testing will be performed. Any confidence intervals pre-
sented will be two-sided at the 95% confidence level.
Baseline characteristics
Baseline descriptions of students recruited and tested
will be presented by treatment group: including means
and standard deviation or numbers and proportions as
appropriate. This will include demographic characteris-
tics, history of sexual behaviours and chlamydia and gon-
orrhoea status (a full list is available in Appendix). These
summaries will be based on observed values and the
number of missing observations for each characteristic
will be reported.
Main outcomes
Recruitment rates (at baseline)
1. We will assess eligibility rates by calculating the
proportion of students who were eligible and were
asked to participate in the study out of the total
number of students who were assessed for
eligibility. Similarly, the proportion of students who
were recruited to the study out of those eligible will
be calculated. All proportions will be presented
with corresponding 95% confidence intervals (CIs).
2. The time taken to recruit 80 participants at each
college will be described. We will calculate the
mean and standard deviation or medians and
inter-quartile ranges as appropriate of the time
taken to recruit 80 participants at each college.
3. Age, gender and ethnicity at baseline will be
presented separately for those recruited to the study
and those eligible but not recruited. We will present
means and standard deviation or numbers and
proportions as appropriate.
Testing and treatment uptake rates, in intervention colleges
only (1 and 4 months after recruitment)
1. The number and proportion of participants in the
intervention group who return at 1 month and
provide a sample out of the total recruited to the
intervention group will be presented. Of those
tested, the number and proportion of participants
with positive test results and the number and
proportion of participants treated will be presented.
These analyses will be repeated for the 4-month
visit. Corresponding 95% CIs will be presented.
Where available, the reasons for non-attendance
will be summarised
2. Time from test to treatment of positives will be
described. Of the participants who attended the
1-month intervention visit, were tested and
received a positive test result we will calculate
the mean and standard deviation or medians
and inter-quartile ranges as appropriate of the
time between the sample being taken and the
time treatment was received. This will be repeated
for the 4-month visit.
3. The number of partners confirmed treated per
index case will be described. In addition, we will
report the number of partner notifications raised
and addressed, the number of participants who
confirm partner treated, the number of participants
referred to a GUM clinic and, therefore, partner
notification responsibility passed to clinic and the
number of participants with no information
regarding treatment.
Follow-up rates (at 7 months)
1. The number and proportion of participants who
return at month 7 and provide a sample out of the
total recruited will be presented by treatment
group. Of those tested, the number and proportion
of participants with positive test results and the
number and proportion of participants treated will
be presented. Corresponding 95% CIs will be
presented.
2. The number and proportion of participants
completing the final questionnaire will be
presented. Descriptions of participants’ responses by
Phillips et al. Trials  (2018) 19:312 Page 5 of 7
treatment group will be presented (including data
on healthcare usage), by means and standard
deviation or numbers and proportions as
appropriate. We will present the number of repeat
follow-up attempts for non-attendees at 7-month
follow-up.
Prevalence of chlamydia in participants at each college at
baseline and at 7 months
Of those tested, the number and proportion of partici-
pants with positive test results will be presented for each
college at baseline and at 7 months.
Sensitivity analysis
Missing data analysis As this is a feasibility study the
levels of data completion and follow-up rates are import-
ant feasibility outcomes. Therefore, no formal analysis
will be undertaken to account for missing data. All
summaries will be based on observations only and the
number of missing observations for each characteristic
will be reported.
Harm data
Participating student and college staff views of potential
harms of on-site rapid tests and treatment will be sought
and examined in the qualitative interviews. Analysis
details will be described elsewhere.
Trial status
Recruitment was completed in October 2016. Final
follow-up concluded in August 2017.
Conclusion
Findings from this study are intended to assess the feasi-
bility of running a future definitive trial to investigate
whether a FE college-based TnT model leads to a reduc-
tion in prevalence of chlamydia. In this article, we have
described the TnT statistical analysis plan which pro-
vides details about how data from the TnT feasibility
trial will be analysed. The protocol for the trial is pub-
lished by Kerry-Barnard et al. (in press). By publishing
our statistical analysis plan, we believe that we will en-
sure a more balanced, accurate and complete report of
our final results.
Appendix
Baseline characteristics
The following baseline characteristics will be sum-
marised by treatment group:
1. Age
2. Sex
3. Ethnicity
4. Female sexual preference
5. Male sexual preference
6. Age at first sex
7. Number of sexual partners in last year
8. New sexual partner in the past 6 months
9. Type of female contraception
10. Condom use
11. Last sexually transmitted infection (STI) check-up
12. STI history
13. Antibiotics received for an infection in the last 2
weeks
14. Which antibiotics
15. Any symptoms in the past 6 months (female)
16. Any symptoms in the past 6 months (male)
17. Smoker status
18. Vape
19. Alcohol consumption in past month
20. Visited GP in the past 6 months
21. Number of GP visits in the past 6 months
22. Reason for GP visit
23. Visited GUM clinic in the past 6 months
24. Number of GUM clinical visits in the past
6 months
25. Visited walk-in clinic in the past 6 months
26. Number of visits to a walk-in clinical in the past
6 months
27. Visited A&E/hospital in the past 6 months
28. Number of visits to A&E/hospital in the past
6 months
29. Attended healthcare facility for sexual health
reasons
Abbreviations
CI: Confidence interval; CONSORT: Consolidated Standards of Reporting Trials;
FE: Further education; GUM: Genitourinary medicine; ICC: Intraclass
correlation coefficient; REDCap: Research Electronic Data Capture; SGUL: St
George’s, University of London; STI: Sexually transmitted infections; TnT: Test
n Treat
Acknowledgements
We are very grateful to staff and students at the following London FE
colleges: Kingston College, Lambeth College, Lewisham Southwark College
(LESOCO) and South Thames College (Merton and Wandsworth campuses).
Funding
The research project is funded by NIHR Research for Patient Benefit: PB-PG-
1014-35007. The funding body will have no role in the design of the study,
the collection, analysis or interpretation of the data, or the write-up of the
manuscript.
Authors’ contributions
RP and FR are the trial statisticians and drafted and finalised the first version
of the statistical analysis plan. FR was the statistician on the grant
application. PO is a professor of general practice and is the chief investigator
for the study. SKB is the trial manager and a co-investigator on the study.
PO, SKB and FR with others designed the study and obtained the funding.
All authors commented on initial drafts and approved the final manuscript.
Phillips et al. Trials  (2018) 19:312 Page 6 of 7
Ethics approval and consent to participate
Ethics approval was granted by the NRES Committee Bromley ref. 15/LO/
1929. All patients are to provide written informed consent prior to
randomisation.
Competing interests
The authors declare that they have no competing interests.
Author details
1School of Population Health & Environmental Sciences, Faculty of Life
Sciences and Medicine, King’s College London, London, UK. 2Population
Health Research Institute St George’s, University of London, London, UK.
Received: 29 September 2017 Accepted: 4 May 2018
References
1. Oakeshott P, Aghaizu A, Reid F, Howell-Jones R, Hay PE, Sadiq ST, et al.
Frequency and risk factors for prevalent, incident, and persistent genital
carcinogenic human papillomavirus infection in sexually active women:
community based cohort study. BMJ. 2012;344:e4168.
2. Oakeshott P, Aghaizu A, Hay P, Reid F, Kerry S, Atherton H, et al. Is
Mycoplasma genitaliium in women the ‘new chlamydia’? Community-based
prospective cohort study. Clin Infect Dis. 2010;51:1160–6.
3. Oakeshott P, Kerry S, Aghaizu A, Atherton H, Hay S, Taylor-Robinson D, et al.
Randomised controlled trial of screening for Chlamydia trachomatis to
prevent pelvic inflammatory disease: the POPI (prevention of pelvic
infection) trial. Br Med J. 2010;340:1642.
4. Aghaizu A, Reid F, Kerry S, Hay PE, Mallinson H, Jensen JS, et al. Frequency
and risk factors for incident and redetected Chlamydia trachomatis infection
in sexually active, young, multi-ethnic women: a community based cohort
study. Sex Transm Infect. 2014;90:524–8.
5. National Chlamydia Coalition. Getting more young women screened for
chlamydia: findings from qualitative research, vol. 3; 2011. p. 1–17.
6. Public Health England. Opportunistic chlamydia screening of young adults
in England. London: Public Health England; 2014.
7. van den Broek IV, van Bergen JE, Brouwers EE, Fennema JS, Gotz HM,
Hoebe CJ, et al. Effectiveness of yearly, register based screening for
chlamydia in the Netherlands: controlled trial with randomised stepped
wedge implementation. BMJ. 2012;345:e4316.
8. McClean H, Sullivan AK, Carne CA, Warwick Z, Menon-Johansson A,
Clutterbuck D, on behalf of the National Audit Group of the British
Association for Sexual Health and HIV. UK national audit against the key
performance indicators in the British Association for Sexual Health and HIV
Medical Foundation for AIDS and Sexual Health Sexually Transmitted
Infections Management Standards. Int J STD AIDS. 2012;23(10):742–7.
9. Horner PJ. Azithromycin antimicrobial resistance and genital Chlamydia
trachomatis infection: duration of therapy may be the key to improving
efficacy. Sex Transm Infect. 2012;88(3):154–6. https://doi.org/10.1136/
sextrans-2011-050385.
10. Adams EJ, Ehrlich A, Turner KM, Shah K, Macleod J, Goldenberg S, et al.
Mapping patient pathways and estimating resource use for point of care
versus standard testing and treatment of chlamydia and gonorrhoea in
genitourinary medicine clinics in the UK. BMJ Open. 2014;4(7):e005322.
11. Turner KM, Round J, Horner P, Macleod J, Goldenberg S, Deol A, et al. An
early evaluation of clinical and economic costs and benefits of
implementing point of care NAAT tests for Chlamydia trachomatis and
Neisseria gonorrhoea in genitourinary medicine clinics in England. Sex
Transm Infect. 2014;90(2):104–11.
12. Gaydos CA, Van Der Pol B, Jett-Goheen M, Barnes M, Quinn N, Clark C, et al.
Performance of the Cepheid CT/NG Xpert Rapid PCR Test for detection of
Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol. 2013;
51(6):1666–72.
13. Guy RJ, Natoli L, Ward J, Causer L, Hengel B, Whiley D, et al. A randomised
trial of point-of-care tests for chlamydia and gonorrhoea infections in
remote Aboriginal communities: Test, Treat ANd GO- the ‘TTANGO’ trial
protocol. BMC Infect Dis. 2013;13:485.
14. Balendra A, Cousins E, Lamplough H, Oakeshott P, Majewska W, Kerry SR.
Pilot study for the ‘Test n Treat’ trial of on-site rapid chlamydia/gonorrhoea
tests and same day treatment. Sex Transm Infect. 2017;93(4):283.
15. Teare MD, Dimairo M, Shephard N, Hayman A, Whitehead A, Walters SJ.
Sample size requirements to estimate key design parameters from external
pilot randomised controlled trials: a simulation study. Trials. 2014;15:264.
16. Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010
Statement: updated guidelines for reporting parallel group randomised
trials. Ann Intern Med. 2010;152 Epub 24 March
17. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
electronic data capture (REDCap)—A metadata-driven methodology and
workflow process for providing translational research informatics support. J
Biomed Inform. 2009;42(2):377–81.
Phillips et al. Trials  (2018) 19:312 Page 7 of 7
